The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belong...

Descripción completa

Detalles Bibliográficos
Autores principales: Zuckerman, Neta, Nemet, Ital, Kliker, Limor, Atari, Nofar, Lustig, Yaniv, Bucris, Efrat, Bar Ilan, Dana, Geva, Miranda, Sorek-Abramovich, Reut, Weiner, Chen, Rainy, Nir, Bar-Chaim, Adina, Benveniste-Levkovitz, Patricia, Abu Hamed, Ramzia, Regev-Yochay, Gili, Hevkin, Ofra, Mor, Orna, Alroy-Preis, Sharon, Mendelson, Ella, Mandelboim, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2021
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646983/
https://www.ncbi.nlm.nih.gov/pubmed/34763751
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2100974
_version_ 1784610531467853824
author Zuckerman, Neta
Nemet, Ital
Kliker, Limor
Atari, Nofar
Lustig, Yaniv
Bucris, Efrat
Bar Ilan, Dana
Geva, Miranda
Sorek-Abramovich, Reut
Weiner, Chen
Rainy, Nir
Bar-Chaim, Adina
Benveniste-Levkovitz, Patricia
Abu Hamed, Ramzia
Regev-Yochay, Gili
Hevkin, Ofra
Mor, Orna
Alroy-Preis, Sharon
Mendelson, Ella
Mandelboim, Michal
author_facet Zuckerman, Neta
Nemet, Ital
Kliker, Limor
Atari, Nofar
Lustig, Yaniv
Bucris, Efrat
Bar Ilan, Dana
Geva, Miranda
Sorek-Abramovich, Reut
Weiner, Chen
Rainy, Nir
Bar-Chaim, Adina
Benveniste-Levkovitz, Patricia
Abu Hamed, Ramzia
Regev-Yochay, Gili
Hevkin, Ofra
Mor, Orna
Alroy-Preis, Sharon
Mendelson, Ella
Mandelboim, Michal
author_sort Zuckerman, Neta
collection PubMed
description The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.
format Online
Article
Text
id pubmed-8646983
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-86469832021-12-23 The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021 Zuckerman, Neta Nemet, Ital Kliker, Limor Atari, Nofar Lustig, Yaniv Bucris, Efrat Bar Ilan, Dana Geva, Miranda Sorek-Abramovich, Reut Weiner, Chen Rainy, Nir Bar-Chaim, Adina Benveniste-Levkovitz, Patricia Abu Hamed, Ramzia Regev-Yochay, Gili Hevkin, Ofra Mor, Orna Alroy-Preis, Sharon Mendelson, Ella Mandelboim, Michal Euro Surveill Rapid Communication The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Micro-neutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection. European Centre for Disease Prevention and Control (ECDC) 2021-11-11 /pmc/articles/PMC8646983/ /pubmed/34763751 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2100974 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Rapid Communication
Zuckerman, Neta
Nemet, Ital
Kliker, Limor
Atari, Nofar
Lustig, Yaniv
Bucris, Efrat
Bar Ilan, Dana
Geva, Miranda
Sorek-Abramovich, Reut
Weiner, Chen
Rainy, Nir
Bar-Chaim, Adina
Benveniste-Levkovitz, Patricia
Abu Hamed, Ramzia
Regev-Yochay, Gili
Hevkin, Ofra
Mor, Orna
Alroy-Preis, Sharon
Mendelson, Ella
Mandelboim, Michal
The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title_full The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title_fullStr The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title_full_unstemmed The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title_short The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021
title_sort sars-cov-2 lambda variant and its neutralisation efficiency following vaccination with comirnaty, israel, april to june 2021
topic Rapid Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646983/
https://www.ncbi.nlm.nih.gov/pubmed/34763751
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2100974
work_keys_str_mv AT zuckermanneta thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT nemetital thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT klikerlimor thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT atarinofar thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT lustigyaniv thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT bucrisefrat thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT barilandana thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT gevamiranda thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT sorekabramovichreut thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT weinerchen thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT rainynir thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT barchaimadina thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT benvenistelevkovitzpatricia thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT abuhamedramzia thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT regevyochaygili thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT hevkinofra thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mororna thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT alroypreissharon thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mendelsonella thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mandelboimmichal thesarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT zuckermanneta sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT nemetital sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT klikerlimor sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT atarinofar sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT lustigyaniv sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT bucrisefrat sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT barilandana sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT gevamiranda sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT sorekabramovichreut sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT weinerchen sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT rainynir sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT barchaimadina sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT benvenistelevkovitzpatricia sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT abuhamedramzia sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT regevyochaygili sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT hevkinofra sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mororna sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT alroypreissharon sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mendelsonella sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021
AT mandelboimmichal sarscov2lambdavariantanditsneutralisationefficiencyfollowingvaccinationwithcomirnatyisraelapriltojune2021

Ejemplares similares